HLB Group's bio chief, Chair Kim Tae-han, bought 210,000 shares of HLB Innovation last month. The equity was purchased on the market on the 18th, after Kim joined HLB Group.
HLB stated accordingly through a "report on large holdings of stocks, etc." disclosed on the 3rd. The disclosure followed Kim's appointment as a registered executive of HLB as of the 31st of last month, which newly categorized Kim as a related party of the affiliate group. HLB Group hired Kim, the first CEO of Samsung Biologics, in January.
Before Kim, HLB Group Chair Jin Yang-gon also bought 207,000 shares this year over four purchases. The company said it was a meaningful move that shows agreement with and trust in the group's mid- to long-term growth strategy. HLB Innovation is continuing an improvement trend in earnings centered on the semiconductor parts business. On a separate basis last year, sales were 32.2 billion won, up 27% from the previous year, and operating profit turned to black at 800 million won.
At the same time, through its subsidiary Verismo, it is pursuing the development of a next-generation anticancer CAR-T (chimeric antigen receptor-T) therapy. Verismo plans to release three related research papers at the American Association for Cancer Research (AACR 2026) on the 17th. In particular, the interim phase 1 results of the solid tumor treatment candidate "SynKIR-110" under development by the company were selected as the sole main oral presentation (CTPL) among domestic corporations. AACR is one of the largest cancer research conferences in the world.